SequelSEC

Beam Therapeutics Inc. BEAM

Biological Products, (No Diagnostic Substances) · CIK 0001745999 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$139.74M
Fiscal year ended 2025-12-31
Operating income
-$383.69M
Fiscal year ended 2025-12-31
Free cash flow
-$360.05M
Fiscal year ended 2025-12-31

Beam Therapeutics Inc. (BEAM) reported revenue of $139.74M and net income of -$79.99M for the fiscal year ended 2025-12-31. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from Beam Therapeutics Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Beam Therapeutics Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue$139.74M$63.52M$377.71M$60.92M$51.84M$24.00K$18.00K
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$383.69M-$415.57M-$176.48M-$338.48M-$392.46M-$132.76M-$75.15M
Net income-$79.99M-$376.74M-$132.53M-$289.09M-$370.64M-$194.59M-$78.33M
Research & development$409.62M$367.56M$437.38M$311.59M$387.09M$103.18M$54.62M
Weighted-average diluted sharesshares 98.91Mshares 82.31Mshares 77.15Mshares 70.02Mshares 64.23Mshares 46.73Mshares 6.48M
Pretax income-$79.99M-$376.70M-$131.16M-$260.18M-$370.64M-$194.59MUnavailable
Income tax expense$0$39.00K$1.37M$3.41M$0$0$0
Diluted EPS$-0.81$-4.58$-1.72$-4.13$-5.77$-4.19$-14.05
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$113.82M$111.52M$116.81M$87.80M$57.22M$29.60M$20.55M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Beam Therapeutics Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Cash & equivalents$294.94M$281.97M$435.90M$232.77M$559.99M$162.17M$37.22M
Total assets$1.48B$1.10B$1.46B$1.34B$1.47B$451.68M$156.10M
Current assets$1.27B$878.15M$1.21B$1.09B$1.27B$308.32M$94.54M
Total liabilities$242.82M$370.28M$478.38M$608.24M$647.72M$206.12M$55.15M
Current liabilities$96.94M$182.07M$205.56M$223.60M$213.44M$102.34M$29.14M
Total equity incl. NCI$1.24B$733.54M$981.33M$733.47M$826.74M$245.56M-$201.10M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$302.05M
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$10.23M$3.87M$1.62M$9.03M$7.47M$6.31M$7.85M

Cash flow

Beam Therapeutics Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Operating cash flow-$345.10M-$347.25M-$149.20M$22.53M-$66.27M-$95.74M-$72.00M
Capital expenditures$14.95M$8.95M$33.73M$48.95M$46.81M$16.36M$12.52M
Investing cash flow-$121.44M$185.01M$71.84M-$461.34M-$294.14M-$100.12M-$66.66M
Financing cash flow$478.05M$7.74M$276.45M$111.59M$756.14M$322.32M$41.28M
Net change in cash$11.51M-$154.50M$199.09M-$327.22M$395.73M$126.46M-$97.38M
Stock-based compensation$94.24M$120.66M$98.65M$84.32M$43.57M$15.38M$7.03M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$22.29M$21.92M$20.01M$14.15M$7.45M$4.74M$3.50M

Derived

Beam Therapeutics Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Free cash flow-$360.05M-$356.19M-$182.93M-$26.42M-$113.08M-$112.10M-$84.52M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-274.6%-654.3%-46.7%-555.6%-757.0%-553166.7%-417522.2%
FCF margin-257.7%-560.8%-48.4%-43.4%-218.1%-467075.0%-469561.1%
SBC / revenue67.4%190.0%26.1%138.4%84.0%64083.3%39044.4%
Current ratio13.09x4.82x5.89x4.89x5.96x3.01x3.24x
Revenue YoY growth120.0%-83.2%520.0%17.5%215916.7%33.3%Unavailable
Net margin-57.2%-593.1%-35.1%-474.5%-714.9%-810800.0%-435144.4%
R&D / revenue293.1%578.7%115.8%511.5%746.6%429912.5%303438.9%
CapEx / revenue10.7%14.1%8.9%80.4%90.3%68154.2%69544.4%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BEAM in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-04View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-02-24View SEC filing
10-Q · Filed 2025-11-04View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-Q · Filed 2025-05-06View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.